Macopharma

What Macopharma does

Macopharma (legal entity: Maco Productions SAS) is a French medical device company founded in 1977 in northern France and headquartered in Tourcoing. It is a wholly-owned subsidiary of GMPi (Groupe Maco Pharma International) and operates under the leadership of Managing Director/CEO Caroline Hernu. The company specializes in blood processing solutions spanning the transfusion chain, producing single-use blood bag systems (single to quintuple configurations), leukodepletion filters, transfer/pooling/sampling/distribution sets, automated separators (MacoPress Smarter), tube sealers (MacoSeal SE160 and MacoSeal Light), sterile connection devices (Maconnect), and the THERAFLEX MB-Plasma pathogen inactivation platform with the MacoTronic B2 illumination machine. Its flagship technical platform is the DEHT/PAGGSM system — a non-phthalate plasticizer plus additive solution combination developed proactively ahead of the European REACH 2030 ban on DEHP, supported by the SSP+ platelet additive solution (PAS-E) and the THROMBOFLEX TXP leukoreduction filter. Operations span 31 factories, 15 wholly-owned subsidiaries, and direct field sales presence in 84 countries, with manufacturing in France, Tunisia, Poland, and (post-2024) Germany and Serbia. The company is certified to ISO 13485, ISO 14001, ISO 45001, ISO 22301, CE, MDSAP, and (for selected filtration systems) FDA 21 CFR Part 820. The company serves blood centers and blood establishments, hospital blood banks and transfusion services, and research/cord blood/cell therapy laboratories through direct enterprise sales and regional distribution partners. Revenue model is hardware sales of both consumables (recurring revenue from blood bag systems, filters, and processing sets) and capital equipment, supplemented by software/data management for traceability and processing guidelines/services. Pricing is quote-based and not publicly disclosed, reflecting the regulated medical device nature of the products. The most recent disclosed financial figure is €170 million in 2023 sales (per the November 2024 Lmb Technologie acquisition announcement), making Macopharma a mid-sized European medical device player with global reach and a defensible regulatory and IP moat in DEHP-free blood storage.

Name

Macopharma

Legal name

Maco Productions

Website

https://macopharma.de

Company type

Private

Founded year

1977

Operating status

Operating

Short description

Macopharma manufactures blood processing disposables, equipment, and software — including blood bags, leukodepletion filters, automated separators, tube sealers, and pathogen inactivation systems — serving blood centers, hospitals, and research laboratories in 84 countries through direct field sales.

Ownership category

akta.pro rank

Product category

Medical Devices / Blood Processing Equipment

NAICS

Surgical Appliance and Supplies Manufacturing (339113), Medical Equipment and Supplies Manufacturing (3391), Surgical and Medical Instrument Manufacturing (339112)

SIC

Surgical & Medical Instruments & Apparatus (3841), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)

akta.pro primary industry

Parenteral & Injectable Packaging Components (Stoppers, Seals, Syringes, Cartridges) (IMALAIAE)

akta.pro secondary industries

Diagnostic & Laboratory Packaging (Specimen Containers, Transport Tubes) (IMALAIAF), Medical Supplies & Consumables Wholesale (Non-Device) (CRAOAHAE)

Keywords

• Blood processing solutions
• Medical blood collection devices
• Pathogen inactivation systems
• Leukodepletion filtration
• Platelet additive solutions

Headquarters

HQ city

Tourcoing

HQ country

France

HQ region

Europe

Offices16 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Blood Processing Disposables: Single-use blood bag systems, filtration products, transfer sets, sampling sets, pooling sets, and pathogen inactivation sets. Core recurring revenue from consumables used in blood processing.
2. Blood Processing Equipment: MacoPress separators, MacoSeal sealers, Maconnect devices, MacoTronic illumination machines. Capital equipment sales to blood centers and hospitals.
3. Software and Data Management: Data management systems for blood processing traceability and equipment integration.
4. Processing Guidelines and Services: Expertise and processing guidelines supporting healthcare professionals for safer blood components.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

Macopharma manufactures and distributes medical devices for blood collection, processing, storage, and transfusion, offering an integrated portfolio of single-use blood bag systems, automated processing equipment (separators, sealers, illumination machines), pathogen inactivation systems, leukodepletion filters, sterile connection devices, and platelet additive solutions. Products are sold to blood centers, hospitals, and research laboratories across 84 countries, supported by processing guidelines and software for traceability.

Product overview

Macopharma offers an integrated portfolio of blood processing solutions combining disposable products, equipment, software, and processing guidelines. The core offerings include: blood bag systems (single to quintuple configurations) with various anticoagulant/additive solutions; DEHT x PAGGSM as the company's flagship DEHP-free blood storage solution; pathogen inactivation systems (THERAFLEX MB-Plasma, MacoTronic B2, Blueflex, Plasmaflex); platelet processing solutions (Maconnect, SSP+, THROMBOFLEX TXP); automated equipment (MacoPress smarter, MacoSeal SE160, MacoSeal light); leukodepletion filters for red cells, platelets, plasma, and whole blood; transfer, pooling, sampling and distribution sets; and pediatric/phlebotomy solutions. The company serves blood centers, hospitals, and research laboratories across 80+ countries.

Differentiator

Problem solved

Functional benefit

Brands

• INNOV by Macopharma: Innovation program that empowers collaborators and stakeholders to contribute from ideation to incubation and approval phases, raising standards of care by providing sustainable solutions for safe blood components
• SSP+
• DEHT x PAGGSM
• Macopress Smarter
• Maconnect
• MacoSeal
• THERAFLEX MB-Plasma
• MacoTronic B2
• Thromboflex TXP

Products and services

• Blood Bags Systems

Quantifiable outcome

• 20 million+ platelet concentrates stored in SSP+ across 40+ countries
• +2 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

Feature6 records

Partnerships

Nine partnerships are on record, tiered core and minor.

• Lmb TechnologiecoreStrategic or Co-development Partner · 19 November 2024Acquisition of German company Lmb Technologie, a major player in blood industry equipment. Lmb specializes in blood typing, mixers, welding machines, separators, and presses. This acquisition strengthens Macopharma's equipment range and covers the entire value chain. Expected synergies to double equipment business sales. Lmb has operations in Germany (test centre), Serbia (factory and R&D centre), and Turkey (medical activities).
• AABBcoreStrategic or Co-development Partner · 14 May 2024Partnership for educational webinar on plasticizers in blood collection and storage. Webinar 'Advancing Blood Safety: The Evolving Science & Future of Plasticizers' with 941 registrations from 69 countries. AABB provided program moderation and faculty coordination.
• Canadian Blood ServicescoreStrategic or Co-development PartnerCollaborative research partnership on blood storage safety comparing DEHT/PAGGSM and DEHP/SAGM systems. Studies conducted at Canadian Blood Services' netCAD Blood4Research facility with published results in Vox Sanguinis journal. Macopharma supplies blood bags for the studies.
• VitalantcoreStrategic or Co-development PartnerFirst US evaluation of Buffy Coat-derived platelets using Macopharma's DEHT plasticizer systems. Study conducted at Vitalant Innovation Center in Denver, Colorado, demonstrating acceptable component quality and leukoreduction performance.
• Belgian Red CrosscoreStrategic or Co-development PartnerCollaborative multicentric study with Belgian Red Cross Blood Service on DEHT-PAGGSM impact on RBC concentrate quality. Joint research published in scientific literature.
• EFS Bourgogne Franche ComtécoreStrategic or Co-development PartnerCollaborative studies on SAGM vs PAGGSM storage solutions comparing hematocrit measurement methods and RBC integrity. EFS Besançon involved in process preparation studies.
• BureauVeritas LCIEminorStrategic or Co-development PartnerCollaboration on Life Cycle Assessment study for DEHT/PAGGSM RQT74AB reference product. BureauVeritas LCIE performed environmental impact analysis.
• RENOLIT HealthcarecoreTechnology or IntegrationSupplier of Transfufol DEHT 3126 plasticizer used in Macopharma's DEHT/PAGGSM blood bag systems. Critical material supply partnership for DEHP-free products.
• Cord Blood AlliancecoreStrategic or Co-development PartnerCollaboration addressing supply chain challenges in cell therapy manufacturing, including shortage of Hespan, discontinuation of Sepax system marking, and European regulations on plasticizers. Published in Stem Cells Translational Medicine.

Scale indicators8 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• SARSTEDT: German family-owned manufacturer of blood collection tubes, blood bags, and transfusion consumables. Comparable mid-sized competitor serving European blood banks and laboratories with a similar specialty disposables portfolio.
• Asahi Kasei Medical: Manufacturer of leukocyte reduction filters (e.g., Sepacell), plasma fractionation, and blood purification products. Directly comparable to Macopharma's Thromboflex and Plasmaflex leukodepletion filter product lines.
• Cerus Corporation: Developer of INTERCEPT pathogen reduction system for platelets, plasma, and red cells. Directly competes with Macopharma's THERAFLEX MB-Plasma in pathogen inactivation technology, both addressing blood safety for blood centers globally.
• Fresenius Kabi: Major blood component collection and transfusion products manufacturer with global reach. Directly competes with Macopharma in blood bag systems, transfusion sets, and adjacent disposables; both serve blood centers and hospitals via direct enterprise sales.
• Terumo BCT: Global leader in blood component collection, processing, and cell therapy technologies. Competes head-on with Macopharma in apheresis/whole-blood collection sets, separation equipment (COM.TEC, Reveos), and pathogen reduction.
• Haemonetics: Specialty medical device company focused on blood and plasma component collection, processing, and software. Competes with Macopharma in blood center automation (PCS2, NexSys), plasma collection, and traceability software.
• Grifols: Global plasma-derived therapies and blood collection supplies provider. Overlaps with Macopharma in blood bag systems, plasma collection sets, and hospital transfusion products, particularly through Grifols' Bioscience and Diagnostic divisions.

Emerging players

• Helmer Scientific: Specialist in temperature-controlled storage and processing equipment for blood banks and hospitals. Adjacent competitor in the blood processing workflow (storage/handling) but narrower product scope than Macopharma's full-chain offering.

Broad incumbents

• Bio-Rad Laboratories: Global life science and clinical diagnostics company with blood bank testing reagents and quality controls. Overlaps with Macopharma in the blood services ecosystem but focuses on diagnostic screening rather than blood component processing.

Others

• Lmb Technologie: German blood industry equipment maker (agitators, separators, welders, presses) recently acquired by Macopharma. Included as a now-related entity for completeness, illustrating the equipment category Macopharma is consolidating.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries15 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Macopharma